UTL-5g GBL-5g|cas:646530-37-2|西域试剂

UTL-5g GBL-5g,98.97%

产品编号：Bellancom-117082| CAS NO：646530-37-2| 分子式：C₁₁H₈Cl₂N₂O₂| 分子量：271.10

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-117082	￥2500.00	杭州北京（现货）
Bellancom-117082	￥4500.00	杭州北京（现货）
Bellancom-117082	￥8500.00	杭州北京（现货）
Bellancom-117082	￥13500.00	杭州北京（现货）
Bellancom-117082	￥0.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

UTL-5g GBL-5g

产品介绍

UTL-5g (GBL-5g) 是一种抗炎性 TNF-α 抑制剂，具有化学保护和肝脏放射保护作用。UTL-5g 通过抑制 TNF-α等因子降低顺铂引起的肝毒性、肾毒性和骨髓毒性。

生物活性

UTL-5g (GBL-5g), an anti-inflammatory TNF-α inhibitor, has chemoprotective and liver radioprotective effects. UTL-5g lowers hepatotoxicity, nephrotoxicity, and myelotoxicity induced by Cisplatin through TNF-α inhibition among other factors.

体外研究

RAW 264.7 macrophages are transfected with the respective reporter assay plasmids, pretreated with UTL-5g at 1, 10 or 50 µM for 60 min and then challenged with 100 ng/ml LPS. After a 16 h incubation, transcription factor activity is measured. Transcription factors that shows a UTL-5g dose-dependent decrease in activity in two experiments are categorized as being disrupted by UTL-5g.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

UTL-5g (GBL-5g) lowers levels of TGF-β and TNF-α elevated by lung irradiation.
UTL-5g (60 mg/kg; p.o.; daily for 4 days) shows positive effects in increasing the survival rates and extending the survival times.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6, male mice (8-10 weeks)
Dosage:	15, 30, and 60 mg/kg
Administration:	I.p.; before irradiation, daily x 5
Result:	Blood levels of TGF-β were lowered.

Animal Model:	BDF1 female mice
Dosage:	P.o.; daily for 4 days
Administration:	60 mg/kg (30 min before i.p. injection of Cisplatin at 10, 15, and 20 mg/kg respectively on Day 0)
Result:	Increased the survival rate and delayed the time to death for mice treated with 150% of the maximum tolerated dose (MTD) of Cisplatin (15 mg/kg). At 200% of the MTD of Cisplatin (20 mg/kg), treatment of UTL-5g increased the survival rate and delayed the time to death.

体内研究

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	C57BL/6, male mice (8-10 weeks)
Dosage:	15, 30, and 60 mg/kg
Administration:	I.p.; before irradiation, daily x 5
Result:	Blood levels of TGF-β were lowered.

Animal Model:	BDF1 female mice
Dosage:	P.o.; daily for 4 days
Administration:	60 mg/kg (30 min before i.p. injection of Cisplatin at 10, 15, and 20 mg/kg respectively on Day 0)
Result:	Increased the survival rate and delayed the time to death for mice treated with 150% of the maximum tolerated dose (MTD) of Cisplatin (15 mg/kg). At 200% of the MTD of Cisplatin (20 mg/kg), treatment of UTL-5g increased the survival rate and delayed the time to death.

性状

Solid

溶解性数据

In Vitro:

DMSO : 100 mg/mL (368.87 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.6887 mL	18.4434 mL	36.8868 mL
5 mM	0.7377 mL	3.6887 mL	7.3774 mL
10 mM	0.3689 mL	1.8443 mL	3.6887 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (9.22 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (9.22 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。